Read the article: https://insidebigdata.com/2023/12/19/how-cisos-can-enable-productization-of-valuable-data-assets/
Ellie Dobson, VP Product at Apheris, discusses how the rapid adoption of ML has led to data becoming one of the most valuable assets in business. However, for use cases where compliance with regulation and data privacy is of paramount importance, unlocking the full potential of data raises unique challenges.

Read the article: https://insidebigdata.com/2023/12/19/how-cisos-can-enable-productization-of-valuable-data-assets/

GEN published a thoughtful coverage of last month's Bio-IT World plenary keynote where JT from Apheris presented a session on federated learning and fine-tuning for drug discovery.

ADMET liabilities drive 40–45% of clinical attrition, and models break on novel chemistry which is precisely where chemists need them most. Pre-competitive federated networks address this through complementary data collaboration. A walk through the evidence behind the Apheris ADMET Network.

Federated techniques such as federated learning and federated analysis have emerged as a powerful paradigm for enabling multi-center research on sensitive clinical data while preserving patient privacy. In this study we provide a federated leraning framework for ML research.
NEWSLETTER
A quaterly briefing on operationalizing and customizing co-folding, ADMET and antibody developability models. Written by Robin Röhm, co-founder and CEO at Apheris.

Robin Röhm
Co-Founder & CEO
© 2026 Apheris AI GmbH. All rights reserved.